In addition, Brian and colleagues have shown that pacritinib selectively inhibits JAK2, both non-alloreactive T cells specific for nominal antigens and the development of beneficial Tregs, while limiting NK cell function in patients with COVID-19 (168). This evidence concerns the gene JAK2 and COVID-19.